LRRC31

Across TCGA pan-cancer cohorts, LRRC31 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LRRC31 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LRRC31 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC31 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LIHC, and OV are the cancer types where LRRC31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.171	0.549	<.001	57	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	27	view →
OV	DFS	Median	II,III,IV	0.222	0.541	.038	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.307	.016	18	view →
HNSC	DFS	Median	All	0.195	0.710	.019	12	view →
SKCM	OS	Median	III,IV	0.230	0.817	<.001	9	view →
SARC	DFS	Median	All	0.159	0.594	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LRRC31–BLCA (OS)

Open the BLCA breakdown →